Peptide record

TPDB91356

MAC1/16 MAC1/19 MAC1/4 MAC1/6 MAC1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity modified_plain modified
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91356
MAC1/16 MAC1/19 MAC1/4 MAC1/6 MAC1
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb ToxinPred 3.0
modified_plain
Yes
A 13-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GFGMALKLLKKVL-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
13 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial and Antifungal Activity
Macropins and their analogs Activity
Evidence Records 15 records
Evidence 1 Activity

Activity

IC50
IC50 = 10±4 µM
Anticancer
10

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 15±5 µM
Anticancer
15

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

IC50
IC50 = 8±2 µM
Anticancer
8

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

IC50
IC50 = 32±2 µM
Anticancer
32

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

IC50
IC50 = 21±4 µM
Anticancer
21

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 6 Activity

Activity

IC50
IC50 = 23±4 µM
Anticancer
23

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 7 Activity

Activity

IC50
IC50 = 49±9 µM
Anticancer
49

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 8 Activity

Activity

IC50
IC50 = 29±3 µM
Anticancer
29

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 9 Activity

Activity

IC50
IC50 > 100 µM
Anticancer
100 µM

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 10 Activity

Activity

IC50
IC50 = 68±2 µM
Anticancer
68

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 11 Activity

Activity

IC50
IC50 = 12±6 µM
Anticancer
12

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 12 Activity

Activity

IC50
IC50 = 29 µM
Anticancer
29 µM

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 13 Activity

Activity

IC50
IC50 = 15 µM
Anticancer
15 µM

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 14 Activity

Activity

IC50
IC50 = 70 µM
Anticancer
70 µM

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 15 Activity

Activity

IC50
IC50 = 43±11 µM
Anticancer
43

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012